Latest news
April 2, 2013
Preliminary results of a Phase II study indicates that
Axelar’s AXL1717 is efficacious in 2nd line treatment
of patients with lung cancer
READ
MORE
January 21, 2013
Investigator sponsored Phase I/II study of AXL1717
in patients with brain tumors started in the US
READ
MORE
October 1, 2012
Axelar AB appoints Carl Harald Janson as CEO
READ
MORE
June 2, 2012
Axelar AB has presented Phase I/II data of AXL1717
at the American Society of Clinical Oncology (ASCO) Annual
Meeting.
READ
MORE
Poster:
"A novel targeted oral insulin-like growth factor-1
receptor (IGF-1R) inhibitor and its implications for patients
with non-small cell lung cancer (NSCLC): A Phase I clinical
trial.”
SEE
THE POSTER
May 15, 2012
Axelar to present at the annual American Society of
Clinical Oncology (ASCO) meeting in Chicago in June 2012
READ
MORE
Press release December 28, 2011
Axelar initiates a Phase II clinical study with AXL1717
for the treatment of non-small cell lung cancer
READ
MORE
New poster presented at the European
Multidisciplinary Cancer Congress September 26, 2011
Phase I Dose-escalation Study of AXL1717: a Novel Targeted
Oral Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitor
and Its Implications for Patients with Non-small Cell Lung
Carcinoma
READ
MORE
Press release September 26, 2011
Axelar reports good safety profile of AXL1717 in Phase
I/II in cancer patients
READ
MORE
Press release July 07, 2011
Axelar reports completion of the Phase I/II safety
study with AXL1717 in cancer patients
READ
MORE
Press release May 11, 2011
Axelar secures funding for the coming Phase II program
in lung cancer
READ
MORE
Press release April 6, 2011
Axelar announces positive interim results in Phase
I/II study
READ
MORE
News release March 29, 2011
Axelar’s AXL1717 to be presented at the American
Association of Cancer Research (AACR) 102nd Annual Meeting
in Orlando, Florida
READ
MORE
Press release September 07, 2010
First AXL1717 clinical data from ongoing phase I/II
study in cancer patients has been published
READ
MORE
Press release May 17, 2010
AXL1717 clinical data from ongoing phase I/II study
in
cancer patients will be released in connection with the
ASCO meeting in Chicago, June 2010
READ
MORE
Press release April 27, 2010
Axelar’s board strengthened
READ
MORE
Press release November 13, 2009
Axelar AB Presents the New Anticancer Agent AXL1717 at The
AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics in Boston, Massachusetts, USA
READ
MORE
Press release May 06, 2009
Successful Phase I/II Clinical Trial Results from Cancer Patients
Treated with Anticancer Drug from Axelar AB
READ
MORE
Press release June 17, 2008
Axelar initiates phase I/II clinical trial on cancer patients
with the new anti-cancer drug AXL1717
READ
MORE
Press release June 12, 2008
Axelar receives financing for a phase I/II clinical trial
on cancer patients with the new anti-cancer drug AXL1717
READ
MORE
|
